Recall Z-1749-2025— Abbott Molecular, Inc.

Class II · Ongoing

Class II FDA medical device recall by Abbott Molecular, Inc., initiated 2025-04-28. FDA's recall record names no specific 510(k) clearance for this event. Product: Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the simultaneous qualitative detection and differentiation of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens collected by a healthcare provider (HCP), or in anterior nasal swab specimens that are self-collected at a healthcare location, from individuals suspected by their HCP of respiratory viral infection consistent with COVID-19.. Reason: There were reports of an increase in reactive negative controls and false positive results..

Recalling firm
Abbott Molecular, Inc.
Classification
Class II
Status
Ongoing
Initiated
2025-04-28
Firm location
Des Plaines, IL, United States

Product description

Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the simultaneous qualitative detection and differentiation of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens collected by a healthcare provider (HCP), or in anterior nasal swab specimens that are self-collected at a healthcare location, from individuals suspected by their HCP of respiratory viral infection consistent with COVID-19.

Reason for recall

There were reports of an increase in reactive negative controls and false positive results.

Data sourced from openFDA. This site is unofficial and independent of the FDA.